eligibility_summary
Adults with HER2+ gastric/GEJ adenocarcinoma, measurable disease, ECOG 0–2, life ≥3 mo, failed 5‑FU/platinum (or relapse ≥6 mo post‑adjuvant), recovered from prior therapy, adequate labs, consent. Exclude: recent other cancers, CNS mets, GI obstruction/bleed/perf, active autoimmune disease, ILD/pneumonitis, recent trial/immunosupp/live vaccine/surgery, HIV/immunodef, active HBV/HCV/TB, recent infection, CHF/arrhythmia, uncontrolled HTN, recent thrombosis, major psych/neuro/substance abuse, pregnancy, unsafe conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib/II single-arm study in second-line HER2-positive metastatic gastric cancer. Interventions: Disitamab vedotin—an anti-HER2 antibody–drug conjugate with a microtubule-inhibiting payload (cytotoxic ADC) that binds HER2 and kills HER2-expressing tumor cells, Fruquintinib—an oral small-molecule TKI of VEGFR-1/2/3 (anti-angiogenic) that blocks VEGF signaling and tumor neovascularization, Tislelizumab—an anti-PD-1 IgG4 monoclonal antibody (immune checkpoint inhibitor) that restores T-cell activity. Targets/pathways: HER2/ERBB2 on cancer cells, tubulin/microtubules, VEGF–VEGFR pathway in endothelial cells, and PD-1 on T cells in the tumor microenvironment.